Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,650.00
Ask: 1,710.00
Change: 0.00 (0.00%)
Spread: 60.00 (3.636%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Women struggling to crack glass ceiling in top UK companies-report

Wed, 26th Mar 2014 15:17

* Women now hold fifth of FTSE 100 board positions

* Few women on executive committees with only 4 CEOs

* Campaigners push for voluntary change, not quotas (Adds new quotes, numbers, after report launch)

By Belinda Goldsmith

LONDON, March 26 (Reuters) - More women are sitting on theboards of Britain's blue-chip companies but the glass ceilingis yet to crack, with most top jobs still held by men andcompanies needing to do more to promote women, a governmentreport said on Wednesday.

The third annual progress report found women now occupy afifth, or 20.7 percent, of positions in FTSE 100 companies, upfrom 12.5 percent in 2011, within striking distance of a targetfor women to account for one quarter of board seats by 2015.

But campaigners admitted there was still a long way to go aswomen only account for 6.9 percent of senior executive roles inthe FTSE 100 where there are only four women chief executives.

Two companies in the FTSE 100, commodities trader GlencoreXstrata and miner Antofagasta, still haveall-male boards - although they told Reuters they are seekingfemale directors - and 48 FTSE 250 companies have all-maleboards.

Former trade minister Mervyn Davies, leader of thegovernment initiative since 2011, said the figures showed avoluntary drive to boost women around the boardroom table wasworking and ruled out the need for mandatory quotas such asthose introduced in France, Italy, Spain and the Netherlands andplanned for Germany.

He said the key to lasting improvement was encouragingcompanies to drive change within, not legislation or governmentintervention that critics argue can lead to tokenism and "trophydirectors".

"This is about changing the culture of corporate Britain,and using a stick is not the best way to do that," Davies toldReuters after launching the latest report in London.

"Everyone now sees that (having more women on boards) isgreat business sense so the debate is now moving from theboardroom to executive committees."

BUSINESS CREDIBILITY

He said Britain was leading the way at driving corporatechange on a voluntary basis rather than with quotas which arenow being mulled in the European Union.

But he said companies whether public or private had to stepup to the mark and he has written to all companies in the FTSE350 urging them to find ways to boost female representation.

"Failure would again raise the unwelcome proposal ofcompulsory measures. British business credibility is at stakeand we need to redouble our efforts," Davies said.

Minister for Women Maria Miller said companies needed to behonest that the culture in Britain was not neutral and it wasstill "white, male and heterosexual".

The only FTSE 100 female CEOs are Moya Greene at Royal Mail, Carolyn McCall at easyJet, Angela Ahrendts atBurberry and Alison Cooper at Imperial Tobacco.

Capita and Diageo had the highest proportionof women among FTSE 100 boards at 44 percent, followed by RoyalMail, Unilever, and GlaxoSmithKline.

Miller said corporate change was needed to address genderimbalance as well as the pay gap between men and women and ruleson executive pay.

"Women don't need special treatment. They just need an equalplaying field," she said.

With the spotlight on promoting women, several British banksreleased targets on gender balance in their annual results forthe first time this year.

HSBC aims to have women in 25 percent of seniorroles by 2014/15, up from 22.7 percent; Lloyds has atarget of 40 percent by 2020 compared to 28 percent now; andBarclays is eyeing 26 percent by 2018, up 5 points.

Davies, the former chief executive of Standard Chartered, said it was "inconceivable in this day and age" tohave an all-male board or executive committee.

"A company that does not get the mood of society on thisissue actually deserves to go out of business," he said. (Additional reporting by Steve Slater, Editing by AlisonWilliams)

More News
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.